ArticleJournal of cellular and molecular medicine2025
LncRNA SNHG14 Regulated by ZNF460 Promotes Gastric Cancer Progression and Metastasis by Targeting the miR-206/FNDC3A Axis.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Systematic Identification of the Functional lncRNAs During H7N9 Avian Influenza Virus Infection in Mice.Viruses · 2026Article
- LINC00888 Promotes Gastric Cancer Growth and Metastasis by Sponging miR-145-5p to Regulate FZD7 Expression.Combinatorial chemistry & high throughput screening · 2026Article
- Computational identification and validation of non-coding rna biomarkers in gastrointestinal cancer.Functional & integrative genomics · 2025Review
- LncRNA SNHG14 Regulated by ZNF460 Promotes Gastric Cancer Progression and Metastasis by Targeting the miR-206/FNDC3A Axis.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The current study investigated the functional role of long non-coding RNA SNHG14 (lncRNA SNHG14) in gastric cancer (GC) progression and its underlying mechanisms. Compared with para-carcinoma tissues, SNHG14 was upregulated in GC tissues, correlating with a poor prognosis in GC patients. SNHG14 knockdown significantly weakened the proliferation, migration and invasion capabilities of GC cell lines while enhancing the apoptosis ability of GC cells. Simultaneously, SNHG14 overexpression reversed these effects. RNA fluorescence in situ hybridization (FISH) and nucleocytoplasmic separation assays revealed that SNHG14 was primarily located in the cytoplasm of GC cells. Combined sequencing of the miRNAome and transcriptome depicted that miR-206 could be a potential target for SNHG14. Mechanistically, assays such as luciferase reporter, RNA immunoprecipitation (RIP) and RNA pulldown established that lncRNA SNHG14 acted as a sponge for miR-206. This prevented the degradation of its target gene, FNDC3A, playing a tumour-suppressive role in GC. In addition, FNDC3A directly interacted with the SNHG14 promoter and induced transcription, thus facilitating GC progression. Therefore, our research findings suggested a novel pathway to promote GC progression through the FNDC3A/lncRNA SNHG14/miR-206/FNDC3A axis. Moreover, the findings indicated that SNHG14 could become a potential biomarker and therapeutic target for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.